This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.01030-07v1 52/3/937    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Venisse, N. Articles by Couet, W. Search for Related Content PubMed PubMed Citation Articles by Venisse, N. Articles by Couet, W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2008, p. 937-943, Vol. 52, No. 3
0066-4804/08/$08.00+0     doi:10.1128/AAC.01030-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Mechanism-Based Pharmacokinetic-Pharmacodynamic Models of In Vitro Fungistatic and Fungicidal Effects against Candida albicans

Inserm ERI-23, 40 avenue du Recteur Pineau, 86022 Poitiers, France,¹ Université de Poitiers, UFR Médecine-Pharmacie, 6 rue de la Milétrie, 86021 Poitiers, France,² CHU Poitiers, 2 rue de la Milétrie, 86021 Poitiers, France³

Received 6 August 2007/ Returned for modification 12 October 2007/ Accepted 21 December 2007

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) models describing the fungistatic activity of fluconazole and the fungicidal activity of caspofungin were developed using dynamic in vitro models. Antifungal-drug pharmacokinetics was simulated in vitro, assuming a one-compartment model with an elimination half-life of 3 h and using a wide (1 to 10,000) range of initial concentrations. The number of CFUs over time was determined for up to 31 h and used for PK-PD modeling. A model incorporating first-order natural growth and natural death, plus a maximum number of viable Candida cells, was used to characterize Candida growth in the absence of a drug. Fluconazole was considered to inhibit Candida growth and caspofungin to stimulate Candida death according to an E_max pharmacodynamic model. The data were analyzed with Nonmem, using a population approach. A good fit of the data was obtained with satisfactory estimates of PK-PD parameters, especially with drug concentrations producing 50% of the maximal effect: 50% inhibitory concentrations for fluconazole growth inhibition and 50% effective concentrations for caspofungin death stimulation. In conclusion, mechanistic PK-PD models were successfully developed to describe, respectively, the fungistatic and fungicidal activities of fluconazole and caspofungin in vitro. These models provide much better information on the drug effects over time than the traditional PK-PD index based on MICs. However, they need to be further characterized.

Published ahead of print on 7 January 2008.